Latest News - Avedro

Wednesday, August 02, 2017 | Clinical Trials, Avedro

Results From Avedro's Corneal Collagen Cross-Linking Pivotal Phase 3 Corneal Ectasia Studies Published

Avedro announced the publication of 1-year safety and efficacy data from the randomized, controlled pivotal phase 3 clinical trials that supported the FDA approval of the second clinical indicatio…

Read the full story

Tuesday, July 18, 2017 | Management/Leadership, Avedro

Donald J. Zurbay Joins Avedro’s Board of Directors

Avedro announced that Donald J. Zurbay has been elected to its board of directors. A veteran finance executive with more than 27 years in financial operations and accounting, Mr. Zurbay is the former …

Read the full story

Tuesday, June 20, 2017 | Management/Leadership, Avedro

Avedro Names Thomas E. Griffin Chief Financial Officer

Avedro announced that Thomas E. Griffin has joined the company as chief financial officer (CFO). Mr. Griffin has more than 25 years of executive management experience at emerging growth medical techno…

Read the full story

Thursday, June 01, 2017 | Clinical Trials, Avedro

Results From Avedro's Landmark Corneal Collagen Cross-Linking Pivitol Phase 3 Keratoconus Studies Published

Avedro announced the publication of 1-year safety and efficacy data from the randomized, controlled pivotal phase 3 clinical trials that supported the FDA approval of Avedro’s Photrexa Viscous (…

Read the full story

Thursday, May 04, 2017 | Earnings & Financials, Avedro

Avedro Launches Comprehensive Effort to Secure Coverage and Facilitate Reimbursement of FDA-Approved Corneal Cross-Linking Procedure

Avedro announced a comprehensive effort to secure commercial coverage and support reimbursement of Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa (ribofl…

Read the full story

Thursday, April 27, 2017 | Earnings & Financials, Avedro

Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline Development

Avedro announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with support from existing investors OrbiMed Advisors and Int…

Read the full story

Wednesday, January 11, 2017 | Miscellaneous, Avedro

First US Service Members Treated with the Only FDA-Approved Cross-Linking Procedure in the US

Avedro has begun selling Photrexa Viscous (riboflavin 5-‘phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5’-phosphate ophthalmic solution) and the KXL System to key mil…

Read the full story

Wednesday, September 28, 2016 | Product Releases, Avedro

First FDA Approved Cross-Linking Procedures Are Performed on Patients in the US with Progressive Keratoconus

Avedro announced that it is now shipping Photrexa Viscous and Photrexa, the drugs used in corneal cross-linking procedures with the KXL System. On April 15, 2016, Avedro received approval from the …

Read the full story

Saturday, September 10, 2016 | Medical Studies, Avedro

Two Studies Demonstrate Promising Results of PiXL Procedure for Noninvasive Treatment of Low Myopia

Non-surgical photorefractive intrastromal corneal collagen cross-linking, or PiXL, is a promising new treatment for vision improvement for low myopia, according to the results of two studies announced…

Read the full story

Thursday, September 08, 2016 | Management/Leadership, Avedro

Avedro Appoints Reza Zadno As Chief Executive Officer

Avedro announced the appointment of Reza Zadno, PhD, medical device entrepreneur and health care senior executive, as the company’s Chief Executive Officer. “We are very pleased to have…

Read the full story

Tuesday, July 19, 2016 | FDA Approval/Clearance, Avedro

Avedro’s Cross-linking Platform Approved by FDA for Corneal Ectasia Following Refractive Surgery

Avedro has received approval from the FDA for its corneal collagen cross-linking platform for the treatment of corneal ectasia following refractive surgery. The approval marks the second indication fo…

Read the full story

Monday, April 18, 2016 | FDA Approval/Clearance, Avedro

Avedro Receives Long-Awaited FDA Approval for its Cross-Linking Platform for Progressive Keratoconus

Avedro has received approval from the FDA for its corneal collagen cross-linking platform, the KXL System, along with two photoenhancers -- Photrexa Viscous and Photrexa -- indicatied fo…

Read the full story

Friday, December 25, 2015 | CE Mark Approval, Avedro

Avedro Announces CE Mark Clearance for its Mosaic Advanced Cross‐Linking System and CEO Transition

Avedro announced that it has received the CE Mark for its Mosaic system, a device that has the potential for nonsurgical improvement for low myopia with a procedure called PiXL (Photorefractive Intras…

Read the full story

Saturday, November 14, 2015 | Earnings & Financials, Avedro

Avedro Completes New $32 Million Round of Financing

Avedro announced the successful completion of a $32 million equity financing led by new investors InterWest and OrbiMed, which also includes several of the company’s existing investors. The addi…

Read the full story

Tuesday, November 03, 2015 | Product Releases, Avedro

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL System

Avedro announced that it has received approval for its KXL cross-linking system from the China Food and Drug Administration (CFDA), according to a company news release. The KXL cross-linking system is…

Read the full story
Load More